Thermo Fisher Scientific c-Myc Monoclonal Antibody (9E10), eBioscience

Applications

Tested Dilution

Publications

Western Blot (WB)

1-5 µg/mL

View 2 publications 2 publications

Immunohistochemistry (Paraffin) (IHC (P))

Assay-Dependent

View 1 publication 1 publication

Immunocytochemistry (ICC/IF)

1:100

-

ELISA (ELISA)

-

View 1 publication 1 publication

Immunoprecipitation (IP)

Assay-Dependent

-

ChIP assay (ChIP)

Assay-dependent

-

Product Specifications

Species Reactivity

Human

Published species

Human

Host/Isotype

Mouse / IgG1

Class

Monoclonal

Type

Antibody

Clone

9E10

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.5 mg/mL

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.2

Contains

0.09% sodium azide

Storage conditions

4° C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_468350

Product Specific Information

Description: The 9E10 antibody reacts with human c-Myc p67; the antibody was raised against a synthetic peptide corresponding to amino acids 408-439 within the carboxy terminal domain of human c-Myc. This antibody can be used to detect myc-tagged protein. The transcription factor c-Myc is a proto-oncogene that is at the focal point in cell cycle regulation, metabolism, apoptosis, differentiation, cell adhesion, and tumorigenesis. In normal cells the expression of c-Myc is tightly regulated but in human cancers c-Myc is frequently deregulated. C-Myc also plays a pivotal role in apoptosis, most notably its connections to the CD95/Fas death receptor pathway. These different biological responses to c-Myc are most likely the result of different overlapping subsets of c-Myc target genes.

Applications Reported: This 9E10 antibody has been reported for use in immunoprecipitation, western blotting, and immunohistochemical staining of formalin-fixed paraffin embedded tissue sections.

Applications Tested: This 9E10 antibody has been tested by immunohistochemistry of formalin-fixed paraffin embedded tissue using low or high pH antigen retrieval and can be used at less than or equal to 5 µg/mL. This 9E10 antibody has also been tested by western blot and can be used 5 µg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Purity: Greater than 90%, as determined by SDS-PAGE.

Aggregation: Less than 10%, as determined by HPLC.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

The c-Myc protein is a 62 kDa transcription factor that is encoded by the c-Myc gene on human chromosome 8q24. c-Myc is commonly activated in a variety of tumor cells and plays an important role in cellular proliferation, differentiation, apoptosis and cell cycle progression. The phosphorylation of c-Myc has been investigated and previous studies have suggested a functional association between phosphorylation at Thr58/Ser62 by glycogen synthase kinase 3, cyclin dependent kinase, ERK2 and C-Jun N terminal Kinase (JNK) in cell proliferation and cell cycle regulation. Studies have shown that c-Myc is essential for vasculogenesis and angiogenesis in tumor development, which distributes blood throughout the cells. The c-myc oncogene (p62 c-myc) is involved in the control of normal cellular proliferation and differentiation, and the deregulated expression of c-Myc induces apoptosis in different cell types. Antibodies against c-myc epitopes recognize overexpressed proteins containing Myc epitope tag fused to either amino- or carboxy-termini of targeted proteins. c-Myc-, N-Myc- and L-Myc-encoded proteins function in cell proliferation, differentiation and neoplastic disease. Amplification of the c-Myc gene has been found in several types of human tumors including lung, breast and colon carcinomas, while the N-Myc gene has been found amplified in neuroblastomas. Translocation of the c-myc locus on chromosome 8 to the immunoglobulin loci on chromosome 14 (heavy chain); 2 (delta light chain); or 22 (light chain) is described in Burkitts lymphoma and other B-cell lymphoproliferative conditions. An aberrant expression of the c-myc gene occurs in tumors of different origins such as colorectal, gastric, gallbladder, hepatic, mammary, ovarian, endometrial, head and neck, pulmonary, prostatic, thyroidal, oral, ocular, nasopharyngeal, endocrine, as well as hematopoietic neoplasms.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.